1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Komipharm International Co., Ltd.

Komipharm International Co., Ltd.

041960.KQ
Komipharm International Co., Ltd.KR flagKOSDAQ
7,550.00
KRW
+140.00
- -
542.69BMarket Cap
Komipharm International Co., Ltd.
041960.KQ
(KOSDAQ)

Recent

price

7,550.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
294.54
330
361.09
505.5
554.75
546.69
511.51
531.63
454.66
507.12
528.94
511.23
516.27
610.91
842.69
742.36
701.8
Revenue per Share
8.97
-2.19
16.52
-1.57
-34.61
-98.33
3.93
-73.94
-185.83
-305.26
-40.08
-63.6
-84.49
-57
188
-102
-89.82
Basic EPS, GAAP
-37.93
-95.58
-286.55
-473.2
-221.11
-228.3
-149.9
-90.39
-115.23
-81.85
-23.63
-34.79
-37.27
-56.28
69.8
-72.06
-90.19
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
98.34
104.25
223.49
271.67
196.49
88.85
89.83
22.52
-175.24
-299.94
-105.51
-169.31
-238.49
-239.55
-51.72
-148.61
-135.22
Book Value per Share
394.87
573.34
562.81
667.91
605.93
857.38
1,066.07
1,354.19
1,226.95
1,076.53
1,101.93
1,019.64
841.05
842.31
883.77
940.49
943.09
Tangible Book Value per Share
62
62
61
52
62
67
74
69
77
70
70
70
77
70
70
71
71
Basic Weighted Avg Shares
18,173
20,301
22,110
26,465
34,454
36,405
37,636
36,641
34,994
35,490
37,160
35,847
39,801
42,647
58,779
52,465
49,993
Sales/Revenue/Turnover
8.9
0.81
3.01
1.79
0.52
-1.56
1.62
-0.41
-17.76
-15.31
-5.85
-14.76
-9.56
-14.71
10.54
3.74
3.5
Operating Margin (%)
968
873
813
1,051
1,962
2,634
3,334
3,511
3,561
3,858
3,740
3,582
3,826
3,529
3,100
2,838
2,703
Depreciation Expense
553
-135
1,011
-82
-2,150
-6,548
289
-5,096
-14,303
-21,363
-2,816
-4,459
-6,514
-3,979
13,113
-7,209
-6,398
Net Income, GAAP
- -
- -
22
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
3.04
-0.66
4.57
-0.31
-6.24
-17.99
0.77
-13.91
-40.87
-60.2
-7.58
-12.44
-16.37
-9.33
22.31
-13.74
-12.8
Profit Margin (%)
4,443
18,690
20,975
-2,733
4,241
16,671
15,416
17,527
10,807
15,874
5,337
15,768
1,581
-2,217
13,702
15,734
15,977
Working Capital
2,774
12,564
23,260
30,059
33,185
30,337
13,614
5,857
3,981
16,117
2,733
13,036
3,315
4,593
9,106
7,126
7,172
LT Debt
27,007
39,237
40,565
44,720
53,159
76,130
99,301
107,304
97,987
76,166
78,101
72,406
65,647
60,015
65,538
72,057
73,324
Total Equity
- -
- -
0.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.91
- -
- -
Return on Invested Capital (%)
- -
- -
5.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.03
- -
8.36
Return on Capital (%)
9.55
-2.16
10.07
-0.59
-16.27
-72.27
4.62
-124.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
25,607
33,546
33,044
LT Borrowings
15,200
6,810
6,810
LT Finance Leases
246
316
362
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
72
72
Market Capitalization
443,241
493,898
601,233

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
68,972
68,487
67,933
Cash, Cash Equivalents & STI
28,450
27,888
24,540
Accounts Receivable, Net
17,504
17,323
19,224
Inventories
15,338
15,184
15,834
Total Current Liabilities
33,904
52,752
51,956
Payables & Accruals
- -
- -
- -
ST Debt
25,607
33,546
33,044
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.4%
-1.21%
9.95%
Free Cash Flow
-46.21%
-65.41%
-204.6%
Net Income, GAAP
-234.12%
-103.8%
-154.97%
Sales/Revenue/Turnover
4.41%
8.35%
-10.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,901
19,153
10,990
15,734
58,779
2025
14,410
13,678
12,480
11,897
52,465
2026
11,939
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
73
94
- -
188
2025
0.68
-45.36
-2.11
- -
-102
2026
11.92
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Kimia Biosciences Ltd. (KIMIABL.BO)
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A (300026.SZ)
Hanshang Group Co., Ltd. (600774.SS)
Mind Medicine (MindMed) Inc. (MMDCF)
CTT Pharmaceutical Holdings, Inc. (CTTH)
Clicks Group Limited (CLS.JO)
Business
Komipharm International Co., Ltd. Komipharm International Co., Ltd. (041960.KQ) is a South Korea-based biopharmaceutical company principally engaged in the development, manufacture, and sale of veterinary vaccines, pharmaceuticals, disinfectants, and bio-fertilizers for livestock including swine, bovine, poultry, canine, and avian species; it also pursues human pharmaceuticals such as anticancer drugs and cancer pain-relieving agents, alongside clinical pathological testing, experimentation, and analysis services. The company's core veterinary offerings encompass vaccines like PRO-VAC BBNE for infectious bronchitis, egg drop syndrome, and Newcastle disease in chickens; H5-AINK against highly pathogenic avian influenza and Newcastle disease; PRO-VAC CORYZA for infectious coryza; PRO-VAC ND-IB and PRO-VAC IB for Newcastle disease and infectious bronchitis; and PRO-VAC ABBNE for multiple avian pathogens, with pharmaceuticals available in injectable, powder, oral solution, topical, and disinfectant forms targeting pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis, and bacterial diseases. Komipharm operates internationally with distribution in Europe, Asia, and Africa, maintains a workforce of approximately 161 employees, and reported veterinary medicine sales of 58.78 billion KRW in 2024, reflecting significant growth from prior years. Founded in 1972 as Korea Microbiological Laboratories Co., Ltd. and renamed Komipharm International Co., Ltd. in September 2004, the company is headquartered at 107 Shihwa Gongdan 1-Ra, Jungwang-Dong, Siheung-Si, Gyeonggi Province, South Korea. Recent developments include increased investment in its Australian subsidiary Komipharm International Australia Pty Ltd, with a noted stake expansion as of mid-2025 and a prior 19.9 billion KRW capital commitment, alongside ongoing R&D in human therapeutics and global market participation such as at VIV Africa 2024.